Table 2.
Study Outcomes
| Outcome | Randomized Cohort | Cross-Over Cohort | ||
|---|---|---|---|---|
| Bevacizumab + Placebo | Bevacizumab + Trebananib | P-value | Bevacizumab + Trebananib | |
| 6m PFS (n, %) | 23/56 (41.1%) | 12/53 (22.6%) | 0.98 | 1/22 (4.5%) |
| OS (median, 95% CI) | 11.5 months (8.4, 14.2) | 7.5 months (6.8, 10.1) | 0.09 | 4.9 months (3.8, 8.4) |
| PFS (median, 95% CI) | 4.8 months (3.8, 7.1) | 4.2 months (3.7, 5.6) | 0.04 | 2.3 months (2.1, 3.2) |
| RR for evaluable patients | 0.99* | |||
| CR | 0 | 0 | 0 | |
| PR | 3/51 (5.9%) | 2/48 (4.2%) | 0 | |
| SD | 16/51 (31.4%) | 9/48 (18.8%) | 0 | |
| PD | 32/51 (62.7%) | 37/48 (77.1%) | 9/9 (100%) | |
*
p-value by the Fisher’s exact test for PR vs SD/PD by treatment arms is 0.99
Abbreviations:
6m PFS: 6-month progression-free survival
CR: complete response
OS: overall survival
PD: progressive disease
PFS: progression free survival
PR: partial response
RR: radiographic response
SD: stable disease